Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Operating Expenses (2016 - 2025)

Adma Biologics (ADMA) has disclosed Other Operating Expenses for 13 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 9.83% year-over-year to $1.2 million, compared with a TTM value of $5.0 million through Dec 2025, up 7.49%, and an annual FY2025 reading of $5.0 million, up 7.49% over the prior year.
  • Other Operating Expenses was $1.2 million for Q4 2025 at Adma Biologics, down from $1.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $5.3 million in Q4 2022 and bottomed at -$52.6 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is -$536704.5, with a median of $1.3 million recorded in 2025.
  • The sharpest move saw Other Operating Expenses soared 110.01% in 2022, then plummeted 87.19% in 2023.
  • Year by year, Other Operating Expenses stood at -$52.6 million in 2021, then skyrocketed by 110.01% to $5.3 million in 2022, then plummeted by 83.44% to $872001.0 in 2023, then skyrocketed by 49.31% to $1.3 million in 2024, then dropped by 9.83% to $1.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for ADMA at $1.2 million in Q4 2025, $1.3 million in Q3 2025, and $1.2 million in Q2 2025.